Conference Reports for NATAP

17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy June 8-10, 2016, Washington DC Back

Tweet

Open-Label, Drug-Drug Interaction Study between Second-generation HIV-1 Maturation Inhibitor BMS-955176 and Tenofovir in Healthy Subjects       Proof-of-concept study supports BMS-955176 as a viable compound that overcomes limitations seen in studies of earlier maturation inhibitor candidates; Phase IIb studies for BMS-955176 will begin in second quarter of 2015     BMS-955176: Antiviral Activity and Safety of a Second-Generation HIV-1 Maturation Inhibitor.....   http://www.natap.org/2015/CROI/croi_36.htm   Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazanavir ± Ritonavir.....   http://www.natap.org/2015/IAS/IAS_25.htm     Second-generation HIV-1 Maturation Inhibitor BMS-955176: Overall Antiviral Activity and Safety Results from the Phase IIa Proof-of-Concept Study (AI468002)......   http://www.natap.org/2015/EACS/EACS_09.htm       Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Analysis.....   http://www.natap.org/2015/CROI/croi_38.htm     Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare.....   http://www.natap.org/2015/newsUpdates/122115_01.htm     Reported by Jules Levin 17th International Workshop on Clinical Pharmacology of   HIV & Hepatitis Therapy; June 8-10, 2016; Washington, DC   H. Sevinsky1, M. Chang2, J. Karkas2, D. Hawthorne1, P. Ravindran1, T. Eley1   1Bristol-Myers Squibb, Research and Development, Princeton NJ, USA; 2Bristol-Myers Squibb, Research and Development, Pennington NJ, USA